Home › Gastrointestinal Stromal Tumors › California › Los Angeles
Gastrointestinal Stromal Tumors clinical trials in Los Angeles, CA
4 studies for Gastrointestinal Stromal Tumors are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
RecruitingPhase 3
- GSK Investigational Site, Los Angeles
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
RecruitingPhase 2
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
RecruitingPhase 1/2
- University of Southern California - Norris Comprehensive Cancer Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
RecruitingPhase 1
- University of Southern California, Los Angeles
Gastrointestinal Stromal Tumors trials in other cities
- Miami, FL8 studies
- New York City, NY7 studies
- Boston, MA7 studies
- Philadelphia, PA6 studies
- Houston, TX6 studies
- San Diego, CA5 studies
- Portland, OR5 studies
- Nashville, TN5 studies
- Omaha, NE5 studies
- Jacksonville, FL4 studies
- Rochester, MN4 studies
- Dallas, TX4 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.